Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nexgel Inc (NXGL)

Nexgel Inc (NXGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,441
  • Shares Outstanding, K 8,476
  • Annual Sales, $ 11,420 K
  • Annual Income, $ -3,000 K
  • EBIT $ -3 M
  • EBITDA $ -3 M
  • 60-Month Beta 0.85
  • Price/Sales 0.47
  • Price/Cash Flow N/A
  • Price/Book 1.05
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.38
  • Most Recent Earnings $-0.12 on 03/31/26
  • Next Earnings Date 04/23/26 [AMC]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Instruments

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5600 +32.86%
on 04/10/26
0.8600 -13.49%
on 04/21/26
+0.0589 (+8.60%)
since 03/20/26
3-Month
0.5600 +32.86%
on 04/10/26
1.7400 -57.24%
on 01/26/26
-0.8360 (-52.91%)
since 01/21/26
52-Week
0.5600 +32.86%
on 04/10/26
2.9680 -74.93%
on 05/12/25
-1.7960 (-70.71%)
since 04/21/25

Most Recent Stories

More News
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

Transaction expected to approximately triple NEXGEL’s annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified...

CELU : 1.2200 (-1.61%)
NXGL : 0.7440 (+15.89%)
NXGLW : 0.0493 (-1.40%)
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products...

NXGL : 0.7440 (+15.89%)
NXGLW : 0.0493 (-1.40%)
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

LANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products...

NXGL : 0.7440 (+15.89%)
NXGLW : 0.0493 (-1.40%)
NXGL Stock: NEXGEL Signs Deal to Triple Revenue and Turn Profitable With Acquisition of Six Commercial-Stage Regenerative Biomaterial Products

After agreeing to acquire a portfolio of regenerative biomaterial products from Celularity, NEXGEL aims to triple revenue to about $35 million and achieve immediate profitability, positioning

NXGL : 0.7440 (+15.89%)
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction

LANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products...

NXGL : 0.7440 (+15.89%)
NXGLW : 0.0493 (-1.40%)
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity

LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products...

NXGL : 0.7440 (+15.89%)
NXGLW : 0.0493 (-1.40%)
NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”),...

NXGL : 0.7440 (+15.89%)
NXGLW : 0.0493 (-1.40%)
NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”),...

NXGL : 0.7440 (+15.89%)
NXGLW : 0.0493 (-1.40%)
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio  ...

CELU : 1.2200 (-1.61%)
NXGL : 0.7440 (+15.89%)
NXGLW : 0.0493 (-1.40%)
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications. Three pipeline...

CELU : 1.2200 (-1.61%)
NXGL : 0.7440 (+15.89%)
CELUW : 0.0096 (+18.52%)

Business Summary

NexGel Inc. is a provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. The company developed and manufactured electron-beam, cross-linked hydrogels. NexGel Inc. is based in Langhorne, Pa.

See More

Key Turning Points

3rd Resistance Point 1.0569
2nd Resistance Point 0.9585
1st Resistance Point 0.8512
Last Price 0.7440
1st Support Level 0.6455
2nd Support Level 0.5471
3rd Support Level 0.4398

See More

52-Week High 2.9680
Fibonacci 61.8% 2.0481
Fibonacci 50% 1.7640
Fibonacci 38.2% 1.4799
Last Price 0.7440
52-Week Low 0.5600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.